魏正宗博士
Wei, JCC (Wei, James Cheng-Chung)

 (7篇)

中山醫學大學醫學研究所 教授
中山醫學大學附設醫院過敏免疫風濕科 主任
2018 van der Heijde, D., Wei, J. C. C., Dougados, M., Mease, P., Deodhar, A., Maksymowych, W. P., . . . Grp, C.-V. S. (2018). Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet, 392(10163), 2441-2451. doi:10.1016/s0140-6736(18)31946-9. [Journal Category: Medicine, General & Internal; Q1]

Times Cited: 45
Baeten, D., Ostergaard, M., Wei, J. C. C., Sieper, J., Jarvinen, P., Tam, L. S., . . . Padula, S. J. (2018). Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the Rheumatic Diseases, 77(9), 1295-1302. doi:10.1136/annrheumdis-2018-213328. [Journal Category: Rheumatology; Q1]

Times Cited: 59
Baraliakos, X., Kivitz, J., Deodhar, A. A., Braun, J., Wei, J. C., Delicha, E. M., . . . Grp, M. S. (2018). Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clinical and Experimental Rheumatology, 36(1), 50-55. [Journal Category: Rheumatology; Q2]

Times Cited: 42
2017 van der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., . . . Kanik, K. S. (2017). Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 76(8), 1340-1347. doi:10.1136/annrheumdis-2016-210322. [Journal Category: Rheumatology; Q1]

Times Cited: 75
2014 Smolen, J. S., Braun, J., Dougados, M., Emery, P., FitzGerald, O., Helliwell, P., . . . Wei, J. C. C., . . . van der Heijde, D. (2014). Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force. Annals of the Rheumatic Diseases, 73(1), 6-16. doi:10.1136/annrheumdis-2013-203419. [Journal Category: Rheumatology; Q1]

Times Cited: 242
2011 Rudwaleit, M., van der Heijde, D., Landewe, R., Akkoc, N., Brandt, J., Chou, C. T., . . . Wei, J. C. C., . . . Sieper, J. (2011). The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases, 70(1), 25-31. doi:10.1136/ard.2010.133645. [Journal Category: Rheumatology; Q1]

Times Cited: 636
2009 Rudwaleit, M., van der Heijde, D., Landewe, R., Listing, J., Akkoc, N., Brandt, J., . . . Wei, J. C. C., . . . Sieper, J. (2009). The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part ii): Validation and final selection. Annals of the Rheumatic Diseases, 68(6), 777-783. doi:10.1136/ard.2009.108233. [Journal Category: Rheumatology; Q1]

Times Cited: 1,436